We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Amicus Therapeutics Inc | NASDAQ:FOLD | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.18 | 1.88% | 9.75 | 9.45 | 9.96 | 9.76 | 9.53 | 9.59 | 1,984,894 | 00:29:59 |
Oral Platform Presentation:
Fabry Disease:
Abstract Title: Trial in progress: An open-label study (AT1001-025) to evaluate the safety and pharmacokinetics of migalastat in patients with Fabry disease and amenable GLA variants and severe renal impairment or end-stage renal disease treated with hemodialysis
Poster Sessions:
Fabry Disease:
Abstract Title: Multiorgan involvement in females with Fabry disease: Results from two Phase III trials and the followME registry (Poster #246)
Abstract Title: Prevalence of migalastat-amenable mutations in patients with Fabry disease from Brazil, Argentina and Colombia (Poster #262)
Abstract Title: Treatment-related benefit and satisfaction in patients with Fabry disease: Insight into patients’ expectations and preferences from the SATIS-Fab study (Poster #189)
Abstract Title: FollowME Fabry Pathfinders registry: Renal effectiveness in a cohort of patients on migalastat treatment for at least three years (Poster #339)
Abstract Title: Exploring the experience of females living with Fabry disease in North America (Poster #8)
Abstract Title: Trial in progress: An open-label study (AT1001-025) to evaluate the safety and pharmacokinetics of migalastat in patients with Fabry disease and amenable GLA variants and severe renal impairment or end-stage renal disease treated with hemodialysis (Poster #165)
Abstract Title: Cardiac biomarkers in Fabry disease (Poster #241)
Abstract Title: Exploring the journey of patients with Fabry disease in Brazil (Poster #346)
Pompe Disease:
Abstract Title: Effect size analysis of cipaglucosidase alfa plus miglustat versus alglucosidase alfa in ERT-experienced adults with late-onset Pompe disease in PROPEL (Poster #232)
Abstract Title: Switching treatment to cipaglucosidase alfa plus miglustat positively affects motor function and quality of life in patients with late-onset Pompe disease (Poster #320)
Abstract Title Baseline demographics of the UK Early Access to Medicines Scheme registry for cipaglucosidase alfa plus miglustat in enzyme replacement therapy-experienced adults with late-onset Pompe disease (Poster #279)
Abstract Title: Minimal clinically important differences in six-minute walking distance in late-onset Pompe disease (Poster #293)
About WORLDSymposiumWORLDSymposium™ is an annual research conference dedicated to lysosomal diseases. WORLD is an acronym that stands for We’re Organizing Research on Lysosomal Diseases. The goal of WORLDSymposium is to provide an interdisciplinary forum to explore and discuss specific areas of interest, research and clinical applicability related to lysosomal diseases. Each year, WORLDSymposium hosts a scientific meeting presenting the latest information from basic science, translational research, and clinical trials for lysosomal diseases. This symposium is designed to help researchers and clinicians to better manage and understand diagnostic options for patients with lysosomal diseases, identify areas requiring additional basic and clinical research, public policy and regulatory attention, and identify the latest findings in the natural history of lysosomal diseases. For more information, please visit www.worldsymposia.org.
About Amicus Therapeutics Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a pipeline of cutting-edge, first- or best-in-class medicines for rare diseases. For more information please visit the company’s website at www.amicusrx.com, and follow on Twitter and LinkedIn.
CONTACTS:
Investors: Amicus Therapeutics Andrew Faughnan
Vice President, Investor Relations afaughnan@amicusrx.com(609) 662-3809
Media: Amicus Therapeutics Diana Moore Vice President, Corporate Communicationsdmoore@amicusrx.com(609) 662-5079
FOLD–G
1 Year Amicus Therapeutics Chart |
1 Month Amicus Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions